Medigrowth signs on as Gold Sponsor of National Pain Week 2026

Medigrowth will back Chronic Pain Australia’s National Pain Week from 26-31 July 2026, joining a campaign focused on the 5.4 million Australians living with chronic pain. The partnership spotlights rising interest in medicinal cannabis and aims to expand evidence-based information, reduce stigma and support informed care decisions.

Why it matters: - National Pain Week reaches a large chronic pain community at a time when demand for reliable treatment information is growing. - Chronic Pain Australia says the campaign supports the 5.4 million Australians living with chronic pain. - The partnership is aimed at reducing stigma around medicinal cannabis and helping people make safer, informed healthcare decisions with qualified health professionals.

What happened: - Medigrowth was announced as Gold Sponsor of National Pain Week 2026. - Chronic Pain Australia’s campaign runs from 26 to 31 July 2026. - Medigrowth also will be named Gold Sponsor of the 2026 National Pain Report. - The sponsorship includes a five-part video series and a longer-form interview focused on questions people living with pain often ask about medicinal cannabis.

The details: - The video series includes: “What’s the Deal with Medicinal Cannabis?”, “What Does Medicinal Cannabis Feel Like?”, “Will People Know I’ve Tried Medicinal Cannabis?”, “Will Medicinal Cannabis Work for Me?” and “Will Medicinal Cannabis Get Me High?” - The interview, “Pain Lives in Women’s Health,” features Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis discussing healthcare leadership and Ellis’s endometriosis journey. - The partnership is framed around patient-centred research and evidence-based education and awareness. - Chronic Pain Australia says the National Pain Survey is the longest-running survey documenting the experiences of Australians living with chronic pain. - The past three National Pain Reports show rising medicinal cannabis use among respondents. - In 2025, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - More than half of respondents either use medicinal cannabis or are interested in it as a treatment option. - Over the same period, reported barriers including cost and driving restrictions eased slightly year on year. - Medigrowth Australia focuses on cannabinoid therapeutics and evidence-based healthcare. - The company conducts clinical research, develops cannabinoid therapeutics for the Australian market and supports patient care through its digital health platform, Azure Health. - Medigrowth says its work spans women’s health, paediatric populations and chronic pain. - The company cites a randomised, double-blind, placebo-controlled clinical trial with Deakin University and Swinburne University on CBD in children and families living with autism. - Medigrowth also points to the EMPOWER Project, a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia is a non-profit, non-government organisation and the national voice for the 3.6 million Australians living with chronic pain. - The organisation was founded in 2001 and runs National Pain Week, PainLink support services and a national network of peer-led Pain Support Groups.

Between the lines: - The sponsorship gives Medigrowth a high-visibility role in a national campaign while aligning the company with a patient advocacy group focused on chronic pain. - The content emphasis suggests an effort to answer common concerns about medicinal cannabis rather than promote it broadly. - The growing share of respondents using or considering medicinal cannabis suggests the treatment is becoming more central in chronic pain conversations, even as cost and driving restrictions remain practical hurdles.

What's next: - Chronic Pain Australia will use National Pain Week to amplify patient voices and push for chronic pain to be recognised as a National Health Priority Area. - Medigrowth will roll out its educational video content and the women’s health interview as part of the campaign. - The 2026 National Pain Report will carry Medigrowth’s Gold Sponsor support. - More information is available from Medigrowth Australia and Chronic Pain Australia.